Workspaces
Log in Sign up

FDA Grants Accelerated Approval to Replimune's TUDRIQEV (RP1) in Advanced Melanoma

Updated

Sources

FDA Grants Accelerated Approval to Replimune's TUDRIQEV (RP1) in Advanced Melanoma

On August 6, 2026, the U.S. Food and Drug Administration (FDA) granted accelerated approval to Replimune Group’s TUDRIQEV (vusolimogene oderparepvec-wtpg), a genetically modified herpes simplex virus-based oncolytic immunotherapy, in combination with Bristol Myers Squibb’s PD-1 inhibitor Opdivo (nivolumab). The approved indication is for the treatment of adults with unresectable advanced cutaneous melanoma who have experienced disease progression on or after a prior anti-PD-1 antibody-based regimen.

This landmark approval represents a significant regulatory turnaround for the oncolytic virus (formerly known as RP1), which had previously faced delays. The accelerated approval was based on objective response rate (ORR) and duration of response (DOR) data from the registration-directed IGNYTE clinical trial.

Commercialization and Financial Scale-Up

On August 14, 2026, during its fiscal first quarter 2027 earnings release, Replimune provided key updates on its commercial launch and financial readiness:

  • Launch Timeline: The commercial launch of TUDRIQEV in the United States is expected to occur within 60 days.
  • Leadership: Michelle DiNapoli has been appointed as Chief Commercial Officer, effective August 18, 2026, to oversee the launch.
  • Financing: Replimune completed a $150 million public financing in August 2026 (yielding $141.0 million in net equity proceeds). This, combined with its June 30 cash balance of $195.3 million, extends the company's cash runway for more than 12 months, fully funding the TUDRIQEV scale-up and the ongoing Phase 3 IGNYTE-3 confirmatory trial.
  • Confirmatory Path: Continued approval is contingent on verifying clinical benefit in the actively enrolling Phase 3 IGNYTE-3 trial, which evaluates overall survival with a primary endpoint readout expected in 2030.

Verbatim Quotes

  • Replimune Group on the TUDRIQEV accelerated approval and launch:

    "On August 6, 2026, the FDA granted accelerated approval for TUDRIQEV (vusolimogene oderparepvec‑wtpg) in combination with nivolumab for adults with unresectable advanced cutaneous melanoma progressing after PD‑1–based therapy. The company expects to launch in the U.S. within 60 days and recently completed a $150 million financing to support commercialization and the IGNYTE‑3 confirmatory Phase 3 trial."

  • Replimune Group on financial performance and runway:

    "Cash, cash equivalents and short-term investments were $195.3 million at June 30, 2026, and, together with $141.0 million of August 2026 equity proceeds, are expected to fund operations for more than 12 months, including the TUDRIQEV commercial scale‑up."

Part of

This finding is an example of a pattern recurring across your work:

Revision history

  • Update the Tudriqev accelerated approval finding with the August 14, 2026 earnings updates, including the 60-day launch window, Michelle DiNapoli's appointment as CCO, and the $150M financing.
    · by the agent
  • Update the Tudriqev accelerated approval finding with the August 14, 2026 earnings updates, including the 60-day launch window, Michelle DiNapoli's appointment as CCO, and the $150M financing.
    · by the agent
  • Update the Tudriqev accelerated approval finding with the August 14, 2026 earnings updates, including the 60-day launch window, Michelle DiNapoli's appointment as CCO, and the $150M financing.
    · by the agent
  • Update the Tudriqev accelerated approval finding with the August 14, 2026 earnings updates, including the 60-day launch window, Michelle DiNapoli's appointment as CCO, and the $150M financing.
    · by the agent
  • Update the Tudriqev accelerated approval finding with the August 14, 2026 earnings updates, including the 60-day launch window, Michelle DiNapoli's appointment as CCO, and the $150M financing.
    · by the agent
  • Update Replimune Tudriqev FDA approval note with full details of the August 6, 2026 accelerated approval, the CTGTAC advisory committee vote, and the regulatory/leadership context.
    · by the agent
  • Update Replimune Tudriqev FDA approval note with full details of the August 6, 2026 accelerated approval, the CTGTAC advisory committee vote, and the regulatory/leadership context.
    · by the agent
  • Update Replimune Tudriqev FDA approval note with full details of the August 6, 2026 accelerated approval, the CTGTAC advisory committee vote, and the regulatory/leadership context.
    · by the agent
  • Write a comprehensive research note on the FDA accelerated approval of Replimune's TUDRIQEV in advanced melanoma.
    · by the agent